Lifevantage (NASDAQ:LFVN) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Lifevantage Corporation (NASDAQ:LFVN)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.54 and traded as low as $6.09. Lifevantage shares last traded at $6.34, with a volume of 175,913 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Lake Street Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Lifevantage in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lifevantage in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Lifevantage Price Performance

The firm has a market cap of $72.39 million, a price-to-earnings ratio of 7.40 and a beta of 0.34. The stock has a 50-day moving average price of $6.39 and a 200 day moving average price of $9.47.

Lifevantage (NASDAQ:LFVN) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.17 by $0.01. The company had revenue of $47.56 million for the quarter, compared to analyst estimates of $54.74 million. Lifevantage had a return on equity of 33.52% and a net margin of 4.43%.Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 15th. Stockholders of record on Monday, December 1st were issued a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend was Monday, December 1st. Lifevantage’s dividend payout ratio is presently 23.38%.

Insider Transactions at Lifevantage

In other Lifevantage news, Director Michael A. Beindorff sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $6.92, for a total transaction of $242,200.00. Following the completion of the sale, the director directly owned 56,413 shares of the company’s stock, valued at $390,377.96. This represents a 38.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 48,607 shares of company stock valued at $330,467. Insiders own 21.95% of the company’s stock.

Institutional Trading of Lifevantage

A number of institutional investors have recently modified their holdings of LFVN. Farther Finance Advisors LLC acquired a new stake in Lifevantage in the second quarter valued at $25,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Lifevantage in the second quarter valued at about $31,000. JPMorgan Chase & Co. boosted its holdings in Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage during the second quarter worth about $76,000. Finally, BNP Paribas Financial Markets increased its holdings in Lifevantage by 2,555.8% in the second quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after buying an additional 5,904 shares in the last quarter. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.